1. Executive Summary (Confidence: High)

Muvon Therapeutics, a spin-off from the University of Zurich (UZH), is a leader in autologous cell-based muscle tissue engineering.^[21] Founded in 2020 and accelerated by the Wyss Zurich Translational Center, the company has developed a proprietary platform for isolating, expanding, and re-implanting a patient’s own muscle precursor cells (MPCs).^[22] In late 2025, Muvon announced positive topline Phase II results for its lead candidate, MPCCOL, in the treatment of female stress urinary incontinence (SUI)—a condition affecting over 200 million women worldwide.^[22] The trial met its primary and secondary endpoints with significant, clinically meaningful improvements and a high safety profile. Muvon’s strategic goal is to establish personalized regenerative treatments as an affordable standard of care, extending its platform to address broader muscular degradation and sarcopenia to prolong human healthspan.^[21]